Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.49 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL748456 | 0.91 | QPCT (0.42) | QPCTQPCTLMTNR1AKDM4EF13A1 | |
| SCHEMBL21820172 | 0.86 | CNR1 (0.36) | QPCTQPCTLMTNR1AMEN1TSHR | |
| SCHEMBL17473831 | 0.86 | MMP9 (0.35) | QPCTQPCTLMTNR1AKDM4ECYP1A2 | |
| SCHEMBL8612877 | 0.85 | MAPK1 (0.36) | QPCTQPCTLMTNR1ABLMLMNA | |
| SCHEMBL17038779 | 0.85 | MTNR1B (0.42) | QPCTQPCTLMTNR1ACYP1A2KMT2A | |
| SCHEMBL13734799 | 0.84 | MAPT (0.33) | QPCTQPCTLMTNR1AMEN1KMT2A | |
| SCHEMBL17473828 | 0.84 | ST14 (0.36) | QPCTQPCTLLMNAMEN1PKM | |
| SCHEMBL14232911 | 0.83 | SMN1; SMN2 (0.43) | MTNR1AKDM4EMEN1TSHRKMT2A | |
| SCHEMBL8226307 | 0.83 | QPCT (0.33) | QPCTQPCTLMTNR1AKDM4EF13A1 | |
| SCHEMBL7631284 | 0.83 | MTNR1A (0.40) | QPCTQPCTLMTNR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| CN-119555822-A | Urine metabolism marker composition for diagnosis of cancer seeds of pan-cancer, screening method and application | 哈尔滨脉图精准技术有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-119324053-A | Model and index for evaluating aging delaying effect of estrogen replacement therapy and application of model and index | 中国科学院北京基因组研究所(国家生物信息中心) | 2025-01-17 | — | — | CN | claimed |
| US-20240400468-A1 | Bionutritional Compositions for Plants and Soils | ENVIROKURE, INCORPORATED (US) | 2024-12-05 | — | — | US | claimed |
| EP-4377280-A1 | BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS | Envirokure Incorporated (US) | 2024-06-05 | — | — | EP | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| CN-115862762-A | Method for predicting ionization efficiency of mass spectrum of compound based on quantitative structure-activity relationship model of COSMO-RS (least squares) and ANN (artificial neural network) algorithm | 大连工业大学 | 2023-03-28 | — | — | CN | claimed |
| WO-2023009636-A1 | BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS | ENVIROKURE, INCORPORATED (US) | 2023-02-02 | — | — | WO | claimed |
| CN-114720615-A | Pancreatic cancer early diagnosis marker and tissue screening method and application thereof | 上海市第一人民医院 | 2022-07-08 | — | — | CN | claimed |
| EP-3766959-A1 | FECAL STORAGE METHOD | Metabologenomics, Inc. (JP) | 2021-01-20 | — | — | EP | claimed |
| US-10603296-B1 | Compositions and methods for diagnosis and treatment of neuromuscular disorders | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2020-03-31 | — | — | US | claimed |
| WO-2019177166-A1 | FECAL STORAGE METHOD | 株式会社メタジェン | 2019-09-19 | — | — | WO | claimed |
| US-20180318260-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2018-11-08 | — | — | US | claimed |
| CN-105765383-B | Cancer of pancreas is with saliva biomarker and has used diagnostic method of the cancer of pancreas with the cancer of pancreas of saliva biomarker | 唾液科技有限公司 | 2018-04-10 | — | — | CN | claimed |
| WO-2017079547-A2 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-05-11 | — | — | WO | claimed |
| US-20160282351-A1 | SALIVARY BIOMARKERS FOR CANCERS, METHODS AND DEVICES FOR ASSAYING THE SAME, AND METHODS FOR DETERMINING SALIVARY BIOMARKERS FOR CANCERS | SALIVATECH CO., LTD. (JP) | 2016-09-29 | — | — | US | claimed |
| EP-3064940-A1 | SALIVARY BIOMARKER FOR CANCER, METHOD AND DEVICE FOR ASSAYING SAME, AND METHOD FOR DETERMINING SALIVARY BIOMARKER FOR CANCER | Salivatech Co., Ltd. (JP) | 2016-09-07 | — | — | EP | claimed |
| CN-105765383-A | SALIVARY BIOMARKER FOR CANCER, METHOD AND DEVICE FOR ASSAYING SAME, AND METHOD FOR DETERMINING SALIVARY BIOMARKER FOR CANCER | 唾液科技有限公司 | 2016-07-13 | — | — | CN | claimed |
| CN-1053233-C | Agent for surface processing of copper and copper alloy | MIKO CO LTD (JP) | 2000-06-07 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | QPCT 1830/4885QPCTL 1024/4885MTNR1A 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.